Relmada Therapeutics (RLMD) Stock Forecast & Price Target
Score
Relmada Therapeutics, Inc. price target
| RLMD | |
|---|---|
| Low | $12.00 |
| Average | $12.00 |
| High | $12.00 |
| Upside vs current price | +185.0% |
The average target of $12.00 is +185.0% versus the current RLMD price of $4.21.
Relmada Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 1 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
4 analysts cover RLMD.
Relmada Therapeutics, Inc. EPS and revenue estimates
RLMD shows the next fiscal years with at least three analysts: 2026 EPS $-0.62, 2027 EPS $-0.80. A thinner year is left off this table.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-0.62 | $10.00M |
| 2027 | $-0.80 | $32.45M |
Is Relmada Therapeutics, Inc. a buy or sell?
Of the 4 analysts covering Relmada Therapeutics, Inc., 4 rate it a buy (1 strong buy and 3 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The RLMD consensus label is Buy, beside 4 buy-side ratings and 0 sell-side ratings.
The average target of $12.00 implies +185.0% versus the current price of $4.21.
Those 4 ratings on RLMD are a headcount, and the label on file is Buy.
Reading the Relmada Therapeutics, Inc. forecast
The RLMD targets sit in a narrow band, from $12.00 to $12.00, around an average of $12.00.
Set next to the $4.21 RLMD quote, that average is +185.0%.
Ratings on the Relmada Therapeutics, Inc. cluster: 4 of 4 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
The RLMD EPS path from 2026 ($-0.62) to 2027 ($-0.80) is falling.
Only 4 analysts cover RLMD, so the average rests on a short list.
Relmada Therapeutics, Inc. forecast questions
What is the RLMD price target?
The published range for RLMD is $12.00 to $12.00, with an average of $12.00. That average is +185.0% versus the current price of $4.21.
Is Relmada Therapeutics, Inc. a buy or sell?
Of the 4 analysts covering Relmada Therapeutics, Inc., 4 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, and the RLMD headcount is 4 buy, 0 hold, and 0 sell.
What is the EPS estimate for Relmada Therapeutics, Inc.?
Analyst EPS estimates for Relmada Therapeutics, Inc.: 2026 $-0.62, 2027 $-0.80.
What is the revenue estimate for Relmada Therapeutics, Inc.?
Analyst revenue estimates for Relmada Therapeutics, Inc.: 2026 $10.00M, 2027 $32.45M.
How many analysts cover RLMD?
4 analysts cover RLMD. Their consensus on RLMD is Buy, across those 4.